- Venetoclax (VEN) demonstrated manageable safety and high response when combined with an anti-CD20 antibody and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with B-cell non-Hodgkin’s lymphoma (NHL).
Why this matters
- This is the first study of VEN in combination with an anti-CD20 monoclonal antibody plus CHOP.
- CAVALLI phase 1b study to investigate VEN in combination with rituximab (R) or obinutuzumab (G) plus CHOP in 56 patients with B-cell NHL.
- Mean patient age, 60.3 (range, 37-79) years.
- Funding: Genentech; AbbVie.
- Maximum tolerated dose not reached for VEN; recommended phase 2 dose was 800 mg on days 4-10 of cycle 1 and days 1-10 of cycles 2-8.
- Responses with VEN+R-CHOP vs VEN+G-CHOP:
- Overall response rate: 87.5% vs 87.5%.
- Complete response (CR): 79.2% vs 78.1%.
- CR in patients with diffuse large B-cell lymphoma (DLBCL): 80.0% vs 100%.
- CR in patients with follicular lymphoma: 70.0% vs 80.0%.
- In patients with DLBCL, 70% 1-year PFS with VEN+R-CHOP vs 100% with VEN+G-CHOP.
- Most common grade 3/4 adverse events with VEN+R-CHOP/VEN+G-CHOP, respectively:
- Neutropenia (54.2%/59.4%), febrile neutropenia (33.3%/25.0%), thrombocytopenia (16.7%/37.5%), and anemia (12.5%/31.3%).
- Limited sample size in each dose cohort.